MedPath

Utility of Sodium Lactate Infusion During Septic Shock

Phase 2
Conditions
Septic Shock
Interventions
Drug: Normal saline
Drug: Sodium Lactate light dose
Drug: Sodium Lactate high dose
Registration Number
NCT03528213
Lead Sponsor
University Hospital, Lille
Brief Summary

ULIS-1 is an open-label pilot study concerning utility of molar sodium lactate in fluid balance in septic shock patients

Detailed Description

ULIS-1 consists in three arms of treatment during the first 24hrs of septic shock treatment.

* normal saline

* sodium lactate 2.5ml/kg in 60min then

* either 0.25 or 0.5ml/kg/h during 24hrs Main criteria is fluid balance at 48hrs

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Presence of septic shock
  • requiring vascular filling within 12 hours after introduction of Noradrenaline. Septic shock is defined as sepsis with persistent hypotension requiring the administration of vasopressors to maintain RTE > 65mmHg.
  • social insurance
Exclusion Criteria
  • pregnancy
  • cardiac arrest
  • more than 50ml/kg of fluid loading
  • chronic renal failure with chronic hemodialysis or the investigators estimate a need for renal replacement therapy in the following 24hrs
  • child C or acute liver failure with PT<40% (unless AVK)
  • plasmatic sodium <120 or >145mmol/l
  • metabolic alkalosis with pH>7.45

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Normal salineNormal salineat physician discretion
Sodium lactate light doseSodium Lactate light dosebolus 2.5ml/kg lactate 60min then 0.25ml/kg/h during 24hrs
Sodium lactate high doseSodium Lactate high dosebolus 2.5ml/kg lactate 60min then 0.50ml/kg/h during 24hrs
Primary Outcome Measures
NameTimeMethod
fluid balanceat 48 hours

fluid balance

Secondary Outcome Measures
NameTimeMethod
fluid balance at day 7Day 7
number of patients deadDay 28
hypokaliemiaDay 2
metabolic alkalosisday 2
death in Intensive Care Unit (ICU)Day 90
death in hospitalDay 90
catecholamines free daysDay 28
new kidney failureDay 28
nosocomial infectionsday 90
hypernatremiaDay 2
ventilator free daysDay 28
renal replacement therapy free daysDay 28
hemodynamic effects assessed by the PICCO® monitoring systemat 48 hours
SOFA (Sequential Organ Failure Assessment)Day 1, Day 2, Day 3, Day 7

Trial Locations

Locations (7)

CH ARRAS

🇫🇷

Arras, France

CH DOUAI

🇫🇷

Douai, France

Ch Dunkerque

🇫🇷

Dunkerque, France

Hopital Victor Provo - Roubaix

🇫🇷

Roubaix, France

Hôpital Roger Salengro, CHU

🇫🇷

Lille, France

CH LENS

🇫🇷

Lens, France

Chu Rouen

🇫🇷

Rouen, France

© Copyright 2025. All Rights Reserved by MedPath